• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

    8/27/25 8:05:00 AM ET
    $MNKD
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNKD alert in real time by email

    DANBURY, Conn. and BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) --  MannKind Corporation (NASDAQ:MNKD) today announced that United Therapeutics Corporation (NASDAQ:UTHR) has exercised its option—granted under the companies' 2018 license and collaboration agreement—to develop a second dry powder inhalation therapy.

    The original agreement, which led to U.S. FDA approval of Tyvaso DPI in May 2022, included an option for United Therapeutics to expand the license to include additional active ingredients. Under the terms of the expanded agreement, MannKind will formulate a second investigational molecule using its proprietary Technosphere® platform, and United Therapeutics will conduct preclinical and clinical development.

    "Building on the success of Tyvaso DPI, we are proud to deepen our collaboration with United Therapeutics to bring innovative patient-centric inhaled therapies to patients living with pulmonary hypertension," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "This next step highlights the strength of our partnership and the versatility of our dry powder formulations and inhalation devices in addressing serious respiratory conditions."

    Under the terms of the expanded agreement, MannKind will receive an upfront payment of $5 million and is eligible to receive up to $35 million in development milestones and 10% royalties on net sales of any resulting product.

    Formulation and development activities for the new investigational molecule will begin immediately.

    About MannKind

    MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.

    We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.

    With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.

    Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.

    Forward-Looking Statements

    Statements in this press release that are not statements of historical fact are forward-looking statements that involve risks and uncertainties. These statements include, without limitation, statements regarding the potential development of an investigational product and receipt of milestone payments and royalties. Words such as "believes", "anticipates", "plans", "expects", "intends", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that continued testing of an investigational drug product may not yield successful results or results that are consistent with earlier testing, and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

    TYVASO DPI is a registered trademark of United Therapeutics Corporation.

    TECHNOSPHERE and MANNKIND are registered trademarks of MannKind Corporation.



    MannKind Contacts:
    Investor Relations
    Ana Kapor, (818) 661-5000
    Email: [email protected]
    
    Media Relations
    Christie Iacangelo, (818) 292-3500
    Email: [email protected]

    Primary Logo

    Get the next $MNKD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MNKD
    $UTHR

    CompanyDatePrice TargetRatingAnalyst
    United Therapeutics Corporation
    $UTHR
    9/26/2025$569.00Outperform
    RBC Capital Mkts
    MannKind Corporation
    $MNKD
    7/16/2025$9.00Buy
    H.C. Wainwright
    United Therapeutics Corporation
    $UTHR
    6/2/2025$405.00Overweight
    Cantor Fitzgerald
    United Therapeutics Corporation
    $UTHR
    4/25/2025Overweight → Equal Weight
    Wells Fargo
    United Therapeutics Corporation
    $UTHR
    4/21/2025$314.00Underperform → Neutral
    BofA Securities
    MannKind Corporation
    $MNKD
    4/10/2025$12.00Outperform
    Mizuho
    MannKind Corporation
    $MNKD
    2/10/2025$11.00Outperform
    Wedbush
    MannKind Corporation
    $MNKD
    12/20/2024$9.00Overweight
    Wells Fargo
    More analyst ratings

    $MNKD
    $UTHR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

    WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced the appointment of Ajay Ahuja, MD, MBA, as Chief Medical Officer, effective today. Dr. Ahuja will report directly to Michael Castagna, PharmD, Chief Executive Officer, and will serve on the company's executive leadership team. "Ajay's deep expertise in medical affairs, clinical development, and global strategy—combined with his background as a practicing physician—will be instrumental as we continue to advance o

    9/29/25 6:05:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary Fibrosis

    United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will host a webcast to review data from the successful TETON-2 pivotal study evaluating the use of nebulized Tyvaso® (treprostinil) Inhalation Solution for the treatment of idiopathic pulmonary fibrosis (IPF) on Sunday, September 28, 2025, at 12:30 p.m. Eastern Time. During the webcast, Steven D. Nathan, M.D., Schar Chair, Advanced Lung Disease and Lung Transplant Program at Inova Fairfax Hospital and Chair of the TETON Steering Committee, will review data that were presented earlier in the day at the European Respiratory Society Congress. He will be joined by Leigh Peterson, Ph.D., Executive Vice President, Product De

    9/19/25 7:00:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum

    United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer, will provide an overview and update on the company during a fireside chat session at the Bernstein 2nd Annual Healthcare Forum in New York. The session will take place on Tuesday, September 23, 2025, from 1:10 p.m. to 1:50 p.m., Eastern Standard Time, and can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed for 90 days. United Th

    9/16/25 7:00:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    $UTHR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on United Therapeutics with a new price target

    RBC Capital Mkts initiated coverage of United Therapeutics with a rating of Outperform and set a new price target of $569.00

    9/26/25 8:07:13 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Mannkind with a new price target

    H.C. Wainwright resumed coverage of Mannkind with a rating of Buy and set a new price target of $9.00

    7/16/25 7:57:36 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on United Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of United Therapeutics with a rating of Overweight and set a new price target of $405.00

    6/2/25 8:55:47 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    $UTHR
    SEC Filings

    View All

    SEC Form 144 filed by United Therapeutics Corporation

    144 - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    9/22/25 4:41:06 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by United Therapeutics Corporation

    144 - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    9/19/25 4:04:01 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by United Therapeutics Corporation

    144 - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    9/11/25 1:32:40 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    $UTHR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairperson & CEO Rothblatt Martine A exercised 8,000 shares at a strike of $120.26 and sold $3,441,322 worth of shares (8,000 units at $430.17) (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    10/2/25 4:30:57 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & GENERAL COUNSEL Mahon Paul A exercised 11,000 shares at a strike of $135.42 and sold $4,802,574 worth of shares (11,000 units at $436.60) (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    10/2/25 4:30:28 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND COO Benkowitz Michael exercised 22,500 shares at a strike of $139.13 and sold $9,490,512 worth of shares (22,500 units at $421.80) (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    10/1/25 4:31:04 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    $UTHR
    Leadership Updates

    Live Leadership Updates

    View All

    MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

    WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced the appointment of Ajay Ahuja, MD, MBA, as Chief Medical Officer, effective today. Dr. Ahuja will report directly to Michael Castagna, PharmD, Chief Executive Officer, and will serve on the company's executive leadership team. "Ajay's deep expertise in medical affairs, clinical development, and global strategy—combined with his background as a practicing physician—will be instrumental as we continue to advance o

    9/29/25 6:05:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases

    MannKind purchased an additional convertible note issued by Thirona BioNonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022MannKind's CEO appointed as a member of the Thirona board of directors DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that has extended its collaboration with Thirona Bio, Inc. ("Thirona") with the purchase of a second convertible note issued by Thirona, and the appointment of Michael Castagna, PharmD as a member of the Thirona board of directors.

    1/5/22 6:05:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IM Therapeutics Announces Appointment of Jonathan Rigby to Board of Directors

    WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of Directors. Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases. IM Therapeutics is developing small molecule oral genetic medicines targeting specific human leukocyte antigen (HLA) variants known to play a strong role in autoimmune diseases. The Company’s lead drug candidate, IMT-002, is in Phase 1b clinical trials in type 1 diabetes (T1D). Patients in the study were preselected for HLA-DQ8, the

    1/27/21 8:00:00 AM ET
    $CLGN
    $UTHR
    $XERS
    Industrial Specialties
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $MNKD
    $UTHR
    Financials

    Live finance-specific insights

    View All

    MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases

    Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet needUpfront cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in cash Upfront cash payment represents a 36% premium to scPharmaceuticals' 90 trading day VWAP, and total consideration of up to $6.35 per share represents up to a 31% premium to scPharmaceuticals' closing price on August 22, 2025Strengthens organization by integrating scPharmaceuticals

    8/25/25 7:30:00 AM ET
    $MNKD
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update

    2Q 2025 revenues of $76.5M, +6% v. 2Q 2024YTD 2025 revenues of $154.9M, +12% v. YTD 2024Advanced pipeline: Submitted sBLA for Afrezza® in pediatric populationMNKD-101: NTM global Phase 3 trial (ICoN-1) enrollment ahead of scheduleMNKD-201: Plan to initiate Phase 2 clinical trial for IPF by YE 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the second quarter 2025 and provided a business update. "The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes," said Mi

    8/6/25 7:05:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025

    DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), announced today that its second quarter 2025 financial results will be released before market open on August 6, 2025. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time to discuss the financial results and provide a business update. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days. About MannKindMannKind Corporation (NASDAQ:MNKD) focuses on the developme

    7/30/25 4:05:00 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    $UTHR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by United Therapeutics Corporation

    SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    11/8/24 4:30:29 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by United Therapeutics Corporation

    SC 13G - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    10/16/24 1:03:48 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by United Therapeutics Corporation (Amendment)

    SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    6/10/24 12:15:17 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care